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Non-adjustment for multiple testing in
multi-arm trials of distinct treatments:
Rationale and justification
Richard A Parker and Christopher J Weir
Abstract
There is currently a lack of consensus and uncertainty about whether one should adjust for multiple testing in multi-arm
trials of distinct treatments. A detailed rationale is presented to justify non-adjustment in this situation. We argue that
non-adjustment should be the default starting position in simple multi-arm trials of distinct treatments.
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Introduction
The multi-arm trial is an efficient trial design which has
been applied in many different settings.1–4 Recent
examples of this trial design include the MS-SMART
trial4 in which three treatments were compared against
a common control group in multiple sclerosis patients,
and the TAME trial comparing four novel treatments
for severe acute malnutrition in children.5 All multi-
arm trials by their nature will involve multiple testing
due to the multiple treatment comparisons, leading to
an increased probability of at least one false-positive
error across all hypotheses of interest. Formally, this is
called the family-wise type-I error rate (FWER), which
is defined as the probability of making at least one
false-positive conclusion among all the multiple hypoth-
eses being tested.6 Multi-arm trial designs that utilise a
common control group are also associated with an
increased risk of multiple false-positive errors; that is,
the probability of K or more errors occurring among
the hypotheses of interest (where K.1).6 Most multipli-
city adjustment methods control the FWER. It is also
possible to additionally control the multiple error rate6
or the expected number of false-positive conclusions.7
In particular, the well-known Bonferroni correction not
only controls the FWER regardless of how many null
hypotheses are true, but also controls the expected
number of false-positive conclusions.7
If multi-arm trials have treatments that are strongly
related (e.g. treatments with different doses), then there
is widespread agreement that a multiplicity adjustment
is necessary.1–3,8,9 However, for multi-arm trials of
distinct treatments, there is a lack of consensus and
uncertainty about whether one should adjust for multi-
ple testing in this setting.1,3,6,8 This lack of consensus
may imply that the arguments against multiplicity
adjustment are weak or insignificant, but we would
argue that this is false. In this article, we aim to provide
a strong rational basis to support non-adjustment in
multi-arm trials of distinct treatments.
The statistical basis of multiple testing
adjustment
The concept of a global null hypothesis
If we are using a multiple testing correction that (as a
minimum) aims to reduce or control the FWER, then
this implies that we wish to control the false-rejection
rate of a global null hypothesis. The global null hypoth-
esis consists of the intersection hypothesis of all null
hypotheses that we are interested in (called a ‘family’ of
null hypotheses). For i= 1,., m null hypotheses, we
can write the following
H0 : H0, 1 \ H0, 2 \ . . . \ H0,m
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In the case of multi-arm trials, each of the null
hypotheses H0,1, H0,2,..., H0,m could indicate that there
is no difference between treatment and control, for
example. The alternative hypothesis would then be the
global union hypothesis
HA : HA, 1 [ HA, 2 [ . . . [ HA,m
This is called ‘union-intersection testing’10 and
implies that if any of the individual null hypotheses are
rejected at an unadjusted alpha significance level, then
so would the global null hypothesis.
The global intersection null hypothesis is more likely
to be rejected as the number of individual null hypoth-
eses increases with multiple testing, and so multiple
testing adjustment is designed to control this inflated
probability of rejection. If treatments are distinct and
we are interested in individual treatment versus control
comparisons, however, then it is difficult to see how the
concept of formulating a global intersection null
hypothesis could be relevant. If the global intersection
null hypothesis is not relevant, then neither is the
FWER.
Nevertheless, a valid counter-argument is that
although we might not be explicitly interested in the
global intersection null hypothesis, the final analysis
results may be reported and interpreted in ways that
implicitly correspond to an underlying global null
hypothesis. This is easily seen if we consider the exam-
ple of a four-arm trial, with three of the arms consisting
of the same treatment given at different doses, and the
fourth arm placebo. In this case, if only one of the
treatment doses shows a significant effect relative to
placebo, then we would conclude that the treatment is
effective. It is therefore recommended to control the
FWER in this situation so that the probability of incor-
rectly concluding that the treatment is effective is below
a pre-specified level. In this case, the overall treatment
efficacy conclusion is the same regardless of which of the
individual doses showed treatment efficacy, and there-
fore, we are implicitly assuming that the rejection of a
global intersection hypothesis is clinical meaningful.
In multi-arm trials of distinct treatments, however,
we are usually interested in each of the treatment com-
parisons individually (e.g. whether drug A is effective
compared to placebo) and their associated false-positive
error rate, often referred to as the comparison-wise error
rate. The comparison-wise error rate is not inflated by
multiple testing.10 Indeed, the expected proportion of
incorrectly rejected hypotheses will not exceed the sig-
nificance level used in the individual tests.10
The single claim of effectiveness
Some authors have emphasised the importance of mak-
ing a ‘single claim of effectiveness’ or defining a ‘clinical
win criteria’ as determining the need for multiple testing
adjustment.6,7,9,10 Howard et al.6 for example, have
suggested that an FWER adjustment is only necessary
if ‘assessing multiple hypotheses within a multi-arm
trial has increased the chance of making a single claim
of effectiveness’. This decision criteria requires careful
definition and consideration because a statement such
as ‘treatment A is effective’ (assuming no other treat-
ments are effective) could be regarded as a ‘single claim
of effectiveness’, even though it has resulted from indi-
vidual interpretation of comparison-wise hypothesis
tests. As above, comparison-wise testing does not
require a multiplicity adjustment. Clearly, the term ‘sin-
gle claim of effectiveness’ must refer to making a con-
clusion such as ‘the treatment is effective’ as in the
dose–response example, which will occur whenever any
of the multiple hypotheses is rejected. If we name spe-
cific treatments (e.g. state that ‘treatment A is effective’)
in our clinical efficacy conclusion, which we invariably
would do when interpreting results from multi-arm
trials of distinct treatments, we have already severed
the connection between the global intersection hypoth-
esis at the study level and our clinical efficacy conclu-
sion. Therefore, researchers should be clear that it is the
content of the clinical efficacy statement that matters
and how it is determined, not how many statements of
effectiveness are stated or how many conclusions given
in a final manuscript. Accordingly, the definition of
‘single claim of effectiveness’ and its specific rationale
should be included in any overall justification of a mul-
tiple testing adjustment.
Rationale for non-adjustment
Issues with multiplicity adjustment
The idea of controlling the FWER to minimise the risk
of a study recommending an ineffective treatment for
use in clinical practice sounds appealing from the statis-
tical perspective. Nevertheless, it does not accord with
the fact that within medicine or public health, multi-
arm trials are usually focussed on the effects of individ-
ual treatments. Knowledge of the effectiveness of at
least one of the treatments is not by itself clinically use-
ful information – the clinician needs to know which
treatments are effective so that they can make an
impact on clinical practice or lead to further investiga-
tion. If one of the treatments was successful, then we
need to know its specific name and pharmacological
properties. How many other treatments were tested
alongside it in the same trial is irrelevant information if
those treatments were distinct. It therefore seems para-
doxical to control overall errors resulting from entire
projects or studies when our main focus in multi-arm
trials is usually in the individual treatment comparisons
themselves. After all, as others have commented, if the
treatments were evaluated in separate trials, there
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would be no expectation that the researcher would need
to make a multiplicity adjustment.6,11
More generally, it is not always clear which hypoth-
eses should be included in the ‘family’ when calculating
the FWER in multiplicity adjustment. The word ‘fam-
ily’ in FWER does not have a universally consistent
definition and its definition needs to be carefully con-
sidered for each multiple testing application.6,12 In our
experience ‘family’ tends to be defined at the level of
the study protocol or the collection of primary hypoth-
eses that are assessed in a final analysis. However, it is
difficult to rationalise why it should be defined at the
study level (e.g. instead of across all trials which include
the same treatment versus control comparisons), other
than relying on convention and pragmatism. Howard
et al. recommend that ‘family’ is taken to encompass
all hypotheses which contribute to a ‘single statement
of effectiveness’;6 but as we have seen, the very defini-
tion of ‘single statement of effectiveness’ is itself uncer-
tain and open to differing interpretations.
Furthermore, setting the type I error rate of the
overall study to be below a certain level obscures the
importance of setting individually appropriate error
rate thresholds according to context and expected costs,
which is strongly recommended in the literature.12–14 If
we are prioritising errors at the study level over errors
in individual treatment comparisons then we are saying
in effect that the impact of the study is more important
than the impact of the clinical treatments, which is con-
trary to common sense.
In addition, treatment recommendations arising
from a study are often based on both clinical and statis-
tical significance15 and may be based on secondary out-
comes and/or safety outcomes as well as primary
outcomes. Therefore, the interpretative environment
used in clinical trials is often much more complex than
that in which a multiple testing adjustment implies.
Statistical evidence from a set of primary null hypoth-
eses may not be sufficient in itself to lead to clinical
impact or substantial cost from a type I error.15 There
is a need to consider the totality of the evidence in
favour of a treatment.16
Another argument against multiplicity adjustment is
that it usually over-complicates interpretation of the
study results.17 Unadjusted and adjusted results may
lead to different conclusions, and adjusted results are
not easy to interpret individually because the degree of
adjustment will depend on the underlying global
hypothesis and how many other treatment comparisons
have been made.
There is also the danger that by focussing too much
on controlling type I error, we overlook the type II
error rate (failing to reject the null hypothesis
even though it is false). The consequence of reducing
the type I error rate is that the type II error rate is
increased.2,13,18,19 This is why performing multiplicity
adjustment is unsupported in exploratory or early
phase studies where type II error is important.
The confirmatory trials argument
It has been suggested that for confirmatory multi-arm
trials, the FWER should be controlled but not for
exploratory trials.1,11 There is some logic in making the
distinction between exploratory and confirmatory. For
confirmatory trials, or trials in which we wish to make
definitive conclusions to settle controversy, the cost of a
false-positive finding is much greater because the treat-
ment is likely to gain wide acceptance or proceed to be
used in clinical practice. However, just because a multi-
arm trial is labelled as ‘confirmatory’ does not mean
that any of the issues associated with multiple testing
adjustment have been resolved. In particular, adjusting
for multiplicity is still inconsistent with how multi-arm
trials of distinct treatments are usually interpreted.
Some might argue that it still makes sense to mini-
mise the danger in interpreting a result as definitive and
‘confirmatory’ if only one treatment arm is significant
among many tested. But we argue that this problem
should not be addressed by multiple testing – it should
be addressed instead by replication and multiple experi-
ments to confirm the results, or by reducing the individ-
ual a significance levels themselves. Indeed, regulatory
agencies usually require ‘statistically compelling and
clinically relevant’ results for the licencing of medicines,
which typically involves replication of the results in at
least one other trial.20 If there was only one pivotal trial
conducted, then the results have to be particularly com-
pelling, with a strong pharmacological rationale and
strong statistical significance.20 Anecdotally this usually
involves setting a statistical significance level of 0.25%,
equating to two independent trials being significant at
5%. In any case, if a type I error rate is of great concern
for a given treatment, then this should be addressed by
the individual a-levels themselves – not indirectly via
controlling the overall FWER.
Consideration of some further objections
Some researchers might argue that it is better to guard
against certain types of risky interpretation in an over-
all study rather than relying on the fact that individual
treatments will be interpreted in isolation. However, it
is not easy to predict how results will be interpreted or
influence subsequent behaviour,15 and inappropriate
adjustment has ethical consequences because it leads to
a larger sample size, lower statistical power or a combi-
nation of these.6 The Bonferroni adjustment in particu-
lar imposes an extreme penalty in this regard.
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Another potential objection is that if the multi-arm
trial has a common control group, then we have to
adjust for multiple testing anyway because the treat-
ment comparisons are related in this way. However,
Howard et al.6 have demonstrated that this concept is
false. The FWER is not increased in multi-arm trials
with a common control group compared to what it
would be if the treatments were tested in independent
trials. Therefore, multiplicity adjustment is not required
purely on the basis of sharing control data.6
Some might argue that the more treatment arms in
a multi-arm trial, the more likely we are to require
adjustment.11 Again, as for confirmatory studies, this
does not solve the real issues covered above. Indeed,
the counter-arguments to adjustment may strengthen
when the number of arms assessed increases, because
the multiplicity adjustment becomes more stringent
and the type II error is further inflated. This could be
compensated by increasing the sample size, but this is
not without cost since it may increase the overall par-
ticipant burden, study duration, or financial cost of
the study.
Discussion
In general, non-adjustment for multiple testing is a
valid and statistically defensible approach for multi-
arm trials of distinct treatments. We do accept how-
ever, that in some circumstances, for example, when
the same treatments are evaluated in multiple sub-
groups,9 adjustment for multiple testing is appropriate.
We also recognise that for confirmatory trials of inves-
tigational medicinal products (IMPs), multiplicity
adjustment may be required by some regulators, for
example, the European Medicines Agency.3,21 We do
not attempt to argue that adjustment is never required.
Our main purpose in writing this article is to provide a
robust case as to why the decision to not to proceed to
perform adjustment is valid as a general proposition.
Any decision to adjust or not adjust should be thought
through carefully with proper consideration of the
study objectives, study design, and analysis.3,22
In this article, we have only considered multiplicity
adjustment of the simple case of multi-arm trials with
distinct treatments. If multi-arm trials have arms of
related treatments, have multiple primary outcomes,
multiple subgroups within treatment arms,9 or include
interim analyses, then it is likely that some form of multi-
plicity adjustment will be required. In particular, if an
overall positive treatment efficacy conclusion does not
depend on which of the individual hypothesis tests are
statistically significant, and does not require all the
individual tests to be significant, then a multiplicity
adjustment is recommended.
An argument often presented in favour of non-
adjustment is that if independent trials were done, then
no multiple testing correction would be performed in
this case.2,3,6,8 In fact, the reasons for non-adjustment
go deeper than this. Although adjusting for multiple
testing enables control of the FWER at the study level
and may make sense theoretically, we would argue that
it does not make good sense from the perspective of
clinical practice and can lead to difficulties with inter-
pretation. It also tends to be logically incompatible
with the main clinical questions of interest.15
Most of the arguments against multiple testing adjust-
ment presented in this article are not new. As far back as
1990, Rothman questioned the validity of posing a global
null hypothesis if there is no strong justification for doing
so.11,18 In his 1998 paper, Perneger19 argued against the
use of the Bonferroni correction in general to correct for
multiple testing. He questioned why a type I error rate
should change depending on the number of tests per-
formed.19 In 1996, Cook and Farewell15 wrote that ‘In
particular, a concern is that testing strategies are fre-
quently adopted with the aim of controlling the experi-
mental type I error rate without considering how this
relates to the questions of main interest’. We think this
concern is still pertinent today. Automatic and unthink-
ing adjustment for multiple testing without thoughtful
consideration is dangerous and potentially unethical. The
decision about whether to adjust for multiple testing is
not an abstract exercise, but one that may have major
ethical implications.6 For example, if an unnecessary
multiple testing adjustment is planned and incorporated
into the sample size calculation, then this may require
the study to have a much larger sample size than needed,
which is a waste of time and resources. This is why we
disagree with sweeping statements promoting the more
widespread use of multiplicity adjustment.23 Careful
thought is needed as to whether multiplicity adjustment
is necessary in each specific circumstance.
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